Broad Nearly Doubles Stock of Illumina Analyzers | GenomeWeb

NEW YORK (GenomeWeb News) – The Broad Institute of MIT and Harvard has bought 22 new Genome Analyzers, nearly doubling its stock of the Illumina-made sequencers, the company said today.

Broad conducts a wide range of biomedical genomics projects, and has worked in a partnership with the San Diego-based life sciences company. Before this purchase, Broad already had 25 of the analyzers in its tool shed, the company said.

In the coming year, Illumina said that it plans to increase the throughput of the analyzer to as much as 95 gigabases of DNA sequence data per run.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.